Overview Energy plans to collect sunlight in orbit and send it to Earth, giving Meta early access to a new source of round-the-clock power
Updated
April 29, 2026 3:20 PM
A corona mass ejection erupts from our sun. PHOTO: UNSPLASH
Overview Energy, a startup focused on space-based power systems, has announced a new agreement with Meta to develop a new source of electricity for data centers. The partnership centres on space solar energy, with an orbital demonstration planned for 2028 and commercial power delivery targeted for 2030.
The deal gives Meta early access to as much as 1 gigawatt of future capacity from Overview’s system. That matters because large technology companies are searching for reliable power sources as demand rises from AI computing and data center expansion.
Overview’s idea is straightforward, though the engineering is ambitious. The company plans to place satellites in orbit that collect sunlight continuously in space. That energy would then be sent to existing solar sites on Earth, where it would be converted into electricity.
Unlike ground-based solar farms, which only generate power when the sun is shining locally, a space-based system is designed to extend power generation beyond daylight hours. In theory, this could help solar facilities produce electricity around the clock without using extra land.
"Space solar technology represents a transformative step forward by leveraging existing terrestrial infrastructure to deliver new, uninterrupted energy from orbit. We're excited to partner with Overview Energy to pioneer innovative energy solutions to advance our AI ambitions and infrastructure", said Nat Sahlstrom, VP of Energy and Sustainability, Meta. "This collaboration demonstrates our commitment to innovation – leveraging cutting-edge technology to strengthen America's energy leadership".
For Meta, the agreement is less about a near-term energy fix and more about securing future options. Major data center operators are increasingly competing for electricity as AI systems require more computing power and more cooling capacity. Traditional energy projects can take years to build, making alternative supply models more attractive.
Overview says its system is designed to work with solar projects that already exist. Instead of building entirely new power plants, the company aims to increase output from current sites by adding energy received from orbit.
"Space is becoming part of America's energy infrastructure", said Marc Berte, CEO of Overview Energy. "Our approach to space solar energy enables hyperscalers and technology providers to secure clean power with reliable siting, and speed to power.” "Together with Meta, we're looking beyond traditional constraints on where and when power can be delivered to meet the growing demand for electricity".
The larger significance of the partnership is what it signals about the energy market. As AI infrastructure expands, companies are beginning to look beyond conventional grids, gas plants and land-based renewables. Technologies once considered experimental are now being explored as part of long-term infrastructure planning.
There is still a long road ahead. Space solar power has been discussed for decades, but commercial deployment remains unproven. Launch costs, regulation and system reliability will all matter.
Even so, the Meta-Overview agreement shows how rising demand for constant power is reshaping where the technology sector looks for its next energy source.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.